Tech Center 1600 • Art Units: 1621 1628 1629 1691
This examiner grants 48% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17771737 | THERAPEUTIC APPROACH FOR TREATING INFLAMMATORY BOWEL DISEASE | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18009312 | Compositions Comprising Antimicrobials and (Bio)-Alkanediols for Skin Protection | Non-Final OA | Symrise AG |
| 15779416 | ORAL PREPARATIONS WITH OMEPRAZOLE OR PANTOPRAZOLE | Final Rejection | SYMRISE AG |
| 16483548 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERIPHERAL ARTERY DISEASE | Non-Final OA | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA |
| 17232397 | METHOD FOR OBTAINING INFORMATION ON RISK OF REDUCED RESPIRATORY FUNCTION IN PATIENT WITH INTERSTITIAL PNEUMONIA | Final Rejection | SYSMEX CORPORATION |
| 16979084 | COMPOSITIONS AND METHODS FOR MUTATIONS ASSOCIATED WITH SUDDEN UNEXPECTED DEATH IN PEDIATRICS | Non-Final OA | Children's Medical Center Corporation |
| 18336712 | THE MODE OF ACTION OF N-MeDCPA ON TRPC CHANNELS | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
| 18001519 | T-TYPE CALCIUM CHANNEL ENHANCER FOR TREATING TAF1 ASSOCIATED NEUROLOGICAL DEFECTS | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 17782643 | INHIBITION OF TMEM16A BY BENZBROMARONE OR NICLOSAMIDE FOR TREATING POLYCYSTIC KIDNEY DISEASE AND/OR POLYCYSTIC LIVER DISEASE | Non-Final OA | FRIEDRICH-ALEXANDER-UNIVERSITÄT ERLANGEN-NÜRNBERG |
| 18001317 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | Non-Final OA | IP2IPO INNOVATIONS LIMITED |
| 18916596 | Novel Beta-Alanine Compositions and Methods of Use Thereof | Non-Final OA | Natural Alternatives International, Inc. |
| 17633560 | METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS | Final Rejection | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
| 17060939 | HEAT SHOCK PROTEIN (HSP) INHIBITION AND MONITORING EFFECTIVENESS THEREOF | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18672929 | METHODS FOR TREATING MUCOPOLYSACCHARIDOSIS | Non-Final OA | University of Miami |
| 18673168 | ANTIVIRAL COMPOUNDS | Non-Final OA | Gilead Sciences, Inc. |
| 18313266 | DARUNAVIR COMBINATION FORMULATIONS | Final Rejection | Gilead Sciences, Inc. |
| 18466041 | IMPROVED ANIMAL FEED COMPOSITIONS AND METHODS OF USE | Non-Final OA | Syngenta Participations AG |
| 16604151 | P38 GAMMA INHIBITORS AND METHOD OF USE THEREOF | Non-Final OA | City of Hope |
| 18620058 | COMBINATION THERAPY FOR PULMONARY HYPERTENSION | Non-Final OA | VIVUS LLC |
| 17127867 | METHODS OF SCHIZOPHRENIA TREATMENT | Non-Final OA | INTRA-CELLULAR THERAPIES, INC. |
| 17923532 | PROGESTOGEN FORMULATIONS AND USES THEREOF | Non-Final OA | Shenzhen Evergreen Therapeutics Co., Ltd |
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Final Rejection | Dompe' farmaceutici SpA |
| 17702452 | ORAL PHARMACEUTICAL IMMEDIATE RELEASE COMPOSITION AND METHOD OF TREATMENT FOR WEIGHT LOSS | Final Rejection | AARDVARK THERAPEUTICS INC. |
| 18019959 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASE ASSOCIATED WITH BETA CORONAVIRUS INFECTION | Non-Final OA | SEN-JAM PHARMACEUTICAL LLC |
| 18040508 | (1R,3S)-3-((5-CYANO-4-PHENYLTHIAZOL-2-YL)CARBAMOYL)CYCLOPENTANE-1-CARBOXYLIC ACID AND DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF AIRWAY DISEASES | Final Rejection | PALOBIOFARMA, S.L. |
| 15734843 | TARGETED TREATMENT OF AUTISM SPECTRUM DISORDER AND OTHER NEUROLOGICAL OR PSYCHIATRIC DISORDERS | Final Rejection | Auttx, LLC |
| 17059297 | NUPR1 INHIBITION FOR TREATING CANCER | Final Rejection | CONSIGLIO NAZIONALE DELLE RICERCHE- NATIONAL RESEARCH COUNCIL ITALY |
| 16936769 | COMPOSITIONS CONTAINING TOAD SECRETION COMPOUNDS | Final Rejection | CAAMTECH LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy